These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15625815)

  • 41. Effect of heliox on albuterol delivery by metered-dose inhaler in pediatric in vitro models of mechanical ventilation.
    Garner SS; Wiest DB; Stevens CE; Habib DM
    Pharmacotherapy; 2006 Oct; 26(10):1396-402. PubMed ID: 16999649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lung deposition of salbutamol in healthy human subjects from the MAGhaler dry powder inhaler.
    Newman S; Malik S; Hirst R; Pitcairn G; Heide A; Pabst J; Dinkelaker A; Fleischer W
    Respir Med; 2002 Dec; 96(12):1026-32. PubMed ID: 12477219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients.
    Dhand R
    Respir Care; 2005 Oct; 50(10):1331-4; discussion 1344-5. PubMed ID: 16185369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative efficacy of inhaled albuterol between two hand-held delivery devices in horses with recurrent airway obstruction.
    Bertin FR; Ivester KM; Couëtil LL
    Equine Vet J; 2011 Jul; 43(4):393-8. PubMed ID: 21496081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation.
    Mazhar SH; Chrystyn H
    J Pharm Biomed Anal; 2009 Sep; 50(2):175-82. PubMed ID: 19443162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stop using the flotation technique and start weighing salbutamol pressurised metered-dose inhalers without dose counters.
    Di Paolo ER; Spaggiari S; Pannatier A; Sadeghipour F; Rochat I; Hafen GM
    Swiss Med Wkly; 2015; 145():w14162. PubMed ID: 26230136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
    Miller CJ; Senn S; Mezzanotte WS
    Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The correlation of urinary levels of albuterol and its metabolites isomers following inhalation from a dry powder inhaler and in vitro particle size characterisation.
    Srichana T; Suedee R; Tanmanee N; Muanpanarai D; Marriott C
    Pulm Pharmacol Ther; 2007; 20(1):36-45. PubMed ID: 16325440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delivered Lung Dose and Aerodynamic Particle Size Distribution of Salbutamol Pressurized Metered Dose Inhaler After Living Under Patients' Realistic Retention Environments.
    Ammari WG; Khalil Mohammad M; Tayyem RF; Martin GP; Royall PG
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):386-395. PubMed ID: 31199708
    [No Abstract]   [Full Text] [Related]  

  • 50. Metered dose inhaler with spacer versus dry powder inhaler for delivery of salbutamol in acute exacerbations of asthma: a randomized controlled trial.
    Lodha R; Gupta G; Baruah BP; Nagpal R; Kabra SK
    Indian Pediatr; 2004 Jan; 41(1):15-20. PubMed ID: 14767083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of large volume spacer, breath-activated and dry powder inhalers in older people.
    Jones V; Fernandez C; Diggory P
    Age Ageing; 1999 Sep; 28(5):481-4. PubMed ID: 10529044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.
    Hampel FC; Martin P; Mezzanotte WS
    J Asthma; 2008 May; 45(4):265-72. PubMed ID: 18446589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide.
    Thorsson L; Geller D
    Respir Med; 2005 Jul; 99(7):836-49. PubMed ID: 15939245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhaled salbutamol from aerolizer and diskus at different inhalation flows, inhalation volume and number of inhalations in both healthy subjects and COPD patients.
    Boshra MS; Almeldien AG; Eldin RS; Elberry AA; Abdelwahab NS; Salem MN; Rabea H; Abdelrahim MEA
    Exp Lung Res; 2019; 45(3-4):84-91. PubMed ID: 31155973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic equivalence of budesonide/formoterol delivered via breath-actuated inhaler vs pMDI.
    Murphy KR; Dhand R; Trudo F; Uryniak T; Aggarwal A; Eckerwall G
    Respir Med; 2015 Feb; 109(2):170-9. PubMed ID: 25596138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique.
    Hindle M; Newton DA; Chrystyn H
    Chest; 1995 Mar; 107(3):629-33. PubMed ID: 7874928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.
    Campbell LM; Anderson TJ; Parashchak MR; Burke CM; Watson SA; Turbitt ML
    Respir Med; 1999 Jul; 93(7):236-44. PubMed ID: 10464829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.